FDA-approved pill clinically proven to treat frustrating low sexual desire in women

 The U.S. Food and Drug Administration (FDA) has approved Addyi® (flibanserin 100 mg) for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in women <65 years. This long-awaited decision closes a gap in care for millions of postmenopausal women experiencing frustrating low sexual desire and marks a historic first approval for the FDA. Addyi is the first and only FDA-approved pill clinically proven to treat frustrating low sexual desire in women, is now approved for use in women who have gone through menopause.